;

38.42 USD

Opening hours: 09:30 - 16:00 (Eastern Standard Time: 12/25/2024 9:03:18 AM)
Exchange closed, opens in 26 minutes
3.00 USD (3.00%)
-5.79 USD (-5.79%)
-1.13 USD (-1.13%)
3.00 USD (3.00%)
-15.54 USD (-15.54%)
187.57 USD (187.57%)
119.67 USD (119.67%)
283.43 USD (283.43%)

About Xenon Pharmaceuticals Inc

Market Capitalization 2.93B

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

Headquarters (address)

3650 Gilmore Way

Burnaby V5G 4W8 BC

Canada

Phone604 484 3300
Websitehttps://www.xenon-pharma.com
Employees251
SectorHealthcare
IndustryBiotechnology
TickerXENE
ExchangeNASDAQ Stock Exchange
CurrencyUSD
52 week range35.53 - 50.99
Market Capitalization2.93B
P/E trailing-14.07
P/E forward-10.78
Price/Book3.12
Beta1.25
EPS-2.81
EPS Canada (ID:82, base:720) 2.18

CleverShares.com|
2024 ©

1.0.9119.29486